Related Experiment Video
Updated: Aug 8, 2026
09:38
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
Drugs affecting visceral sensitivity: ready for the prime time?
1Department of Internal Medicine and Digestive Pathology, CHU de Nancy, Nancy, France. m.delvaux@chu-nancy.fr
Digestive Diseases (Basel, Switzerland)
|May 16, 2006
Summary
Visceral hypersensitivity is common in functional bowel disorders, but current treatments lack proven efficacy. Reliable tests for visceral hypersensitivity are needed to guide patient selection for therapies.
Area of Science:
- Neurogastroenterology
- Gastrointestinal Physiology
Background:
- Visceral sensitivity is a key factor in functional bowel disorders.
- Neurotransmitters are involved in gut-brain signaling, but lack clinical efficacy for visceral hypersensitivity.
- Current diagnostic methods for visceral hypersensitivity are limited in clinical settings.
Purpose of the Study:
- To review the role of visceral sensitivity in functional bowel disorders.
- To discuss the limitations of current diagnostic tools for visceral hypersensitivity.
- To evaluate the potential of visceral sensitivity as a biomarker for treatment selection.
Main Methods:
- Literature review of studies on visceral sensitivity and functional bowel disorders.
- Analysis of neurotransmitter involvement in gut-brain communication.
- Discussion of diagnostic challenges in clinical practice.
Main Results:
- Visceral hypersensitivity is prevalent in functional bowel disorders.
- No specific neurotransmitter has demonstrated significant clinical efficacy for visceral hypersensitivity.
- Lack of reproducible and clinically feasible tests hinders the use of visceral hypersensitivity for patient stratification.
Conclusions:
- Abnormal visceral sensitivity is a significant feature of functional bowel disorders.
- Current understanding and diagnostic capabilities do not support using visceral hypersensitivity to select patients for specific treatments.
- Further research is needed to develop reliable methods for assessing and targeting visceral hypersensitivity.
Related Concept Videos
01:24Local Anesthetics: Differential Sensitivity of Nerve Fibers
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:30Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...